Sifrol (pramipexole) impact on RLS related quality of life: a 12-weeks observational non-interventional study in patients with primary RLS.

Trial Profile

Sifrol (pramipexole) impact on RLS related quality of life: a 12-weeks observational non-interventional study in patients with primary RLS.

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Oct 2013

At a glance

  • Drugs Pramipexole (Primary)
  • Indications Restless legs syndrome
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 08 Jul 2009 Actual patient number (2093) added as reported by ClinicalTrials.gov.
    • 10 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top